Title | A Drosophila model for LRRK2-linked parkinsonism |
Publication Type | Journal Article |
Year of Publication | 2008 |
Authors | Liu Z, Wang X, Yu YI, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, Smith WW |
Journal | Proc Natl Acad Sci U S A |
Volume | 105 |
Pagination | 2693-8 |
Date Published | 2008 Feb 19 |
ISSN | 1091-6490 |
Keywords | Animals, Animals, Genetically Modified, Disease Models, Animal, Dopa Decarboxylase, Dopamine, Drosophila melanogaster, Gait Disorders, Neurologic, Gene Expression Regulation, Microscopy, Electron, Nerve Degeneration, Parkinsonian Disorders, Protein-Serine-Threonine Kinases, Retina |
Abstract | Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson's disease (PD) with pleiomorphic pathology. Previously, we and others found that expression of mutant LRRK2 causes neuronal degeneration in cell culture. Here we used the GAL4/UAS system to generate transgenic Drosophila expressing either wild-type human LRRK2 or LRRK2-G2019S, the most common mutation associated with PD. Expression of either wild-type human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal degeneration. Expression of LRRK2 or LRRK2-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality. Expression of mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than expression of equivalent levels of wild-type LRRK2. Treatment with l-DOPA improved mutant LRRK2-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase-positive neurons. To our knowledge, this is the first in vivo"gain-of-function" model which recapitulates several key features of LRRK2-linked human parkinsonism. These flies may provide a useful model for studying LRRK2-linked pathogenesis and for future therapeutic screens for PD intervention. |
DOI | 10.1073/pnas.0708452105 |
Alternate Journal | Proc. Natl. Acad. Sci. U.S.A. |
PubMed ID | 18258746 |
PubMed Central ID | PMC2268198 |
Grant List | EY08117 / EY / NEI NIH HHS / United States |